Skip to content
Fowler Lab
Fowler Lab

Predicting antibiotic resistance de novo

  • News
  • Publications
  • Members
  • Research
    • Overview
    • Manifesto
    • Software
    • Reproducibility
  • Teaching
  • Contact
    • PhDs
  • Wiki
Fowler Lab
Fowler Lab

Predicting antibiotic resistance de novo

New publication: Validating a bespoke 96-well plate for high-throughput drug susceptibility testing of M. tuberculosis

Philip Fowler, 28th August 201829th September 2018

This paper, published in Antimicrobial Agents and Chemotherapy, determines the reproducibility and accuracy of minimum inhibitory concentrations for a panel of 14 different anti-TB compounds using a specifically designed 96-well plate (called UKMYC5) manufactured by Thermo Fisher.

Since the UKMYC5 plate is being used by the CRyPTIC consortium to measure the drug susceptibility profiles of >30,000 clinical TB samples collected worldwide between now and 2020, this manuscript lays the foundations for this large and ambitious tuberculosis research project.

It is free to read and download, and the paper briefly mentions my AMyGDA software which we will be using as an independent measuring technique to quality control the measurements made by the laboratory scientists. You can download and AMyGDA software from here. A manuscript is currently under review – you can read a preprint here.

The bacterial growth on the UKMYC5 plates are also being classified by a Citizen Science project I have setup, BashTheBug.

Share this:

  • Share on X (Opens in new window) X
  • Share on Bluesky (Opens in new window) Bluesky
  • Email a link to a friend (Opens in new window) Email
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Mastodon (Opens in new window) Mastodon

Related

antimicrobial resistance clinical microbiology publication tuberculosis

Post navigation

Previous post
Next post

Related Posts

clinical microbiology

New publication: Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

13th January 202113th January 2021

A second Covid-19 publication I’m proud to be (a small) part of has recently published…

Share this:

  • Share on X (Opens in new window) X
  • Share on Bluesky (Opens in new window) Bluesky
  • Email a link to a friend (Opens in new window) Email
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Mastodon (Opens in new window) Mastodon
Read More
antimicrobial resistance

New publication: Differential occupational risks to healthcare workers from SARS-CoV- 2

2nd July 202022nd August 2020

Very pleased and proud to be included on this manuscript, which has been published in…

Share this:

  • Share on X (Opens in new window) X
  • Share on Bluesky (Opens in new window) Bluesky
  • Email a link to a friend (Opens in new window) Email
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Mastodon (Opens in new window) Mastodon
Read More

Updated preprint: A validated cloud-based genomic platform for co-ordinated, expedient global analysis of SARS-CoV-2 genomic epidemiology

23rd January 202528th January 2025

In August 2022 seven laboratories across the world uploaded their SARS-CoV-2 genetics files for processing…

Share this:

  • Share on X (Opens in new window) X
  • Share on Bluesky (Opens in new window) Bluesky
  • Email a link to a friend (Opens in new window) Email
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Mastodon (Opens in new window) Mastodon
Read More

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.

To find out more, including how to control cookies, see here: Cookie Policy
    ©2026 Fowler Lab | WordPress Theme by SuperbThemes